Blueprint
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending 21 July
2017
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
Yes
No x
GlaxoSmithKline plc (the "Company")
Board and Committee changes
GSK
today announces that Dr Laurie Glimcher has been appointed to the
Board of the Company as a Non-Executive Director and has been
deemed a Scientific and Medical Expert. Dr Glimcher will join the
Board on 1 September 2017.
Philip
Hampton, Chairman of GlaxoSmithKline plc, said: "I am delighted Laurie is joining the Board.
Laurie brings a wealth of
expertise in scientific and medical innovation and public health
which will be invaluable to GSK. "
Dr
Glimcher is currently Professor of Medicine at Harvard Medical
School and is CEO, President and an Attending Physician at the
Dana-Farber Cancer Institute.
In
addition to a number of senior leadership positions held at both
Harvard Medical School and Harvard School of Public Health, Dr
Glimcher has also served as Stephen and Suzanne Weiss Dean and
Professor of Medicine at Weill Cornell Medical College and as an
Attending Physician at the New York Presbyterian Hospital/Weill
Cornell Medical Center.
Dr
Glimcher is a member of the Blue Ribbon Panel Advisory Board of
the National Cancer Institute and of the American Asthma
Foundation. She is a Non-Executive Director of the Parker Institute
for Cancer Immunotherapy and of the Waters Corporation, where
she also serves on their Corporate Governance Committee. Dr
Glimcher recently decided to step down from the Board of
Bristol-Myers Squibb Co (BMS) after serving for 20 years on its
Board.
Dr
Glimcher has recently been awarded the Kober Medal from the
American Association of Physicians for a lifetime of achievements
in the field of internal medicine. She has also received the
L'Oreal Laureate Award for her discoveries in immunology, and the
Marion Fay Spencer award for her scholarship and commitment to the
application of sciences to healthcare. She is also a member of the
Lasker Award Jury, a Fellow of the American Academy of Arts and
Sciences, a Member of the National Academy of Medicine, a Member of
the National Academy of Sciences and a Fellow of the Royal Society
of Biology.
On
joining the Board Dr Glimcher will become a member of the Board's
Science and Audit & Risk Committees.
V A
Whyte
Company
Secretary
21 July
2017
Notes
1.
As Non-Executive Director of GSK, Dr Glimcher will receive standard
annual fees of £85,000 per annum. She will also receive a
further £30,000 in respect of her additional duties as a Board
Scientific and Medical Expert. To enhance the link between
Non-Executive Directors and shareholders, at least 25% of her fees
will be paid in the form of Ordinary Shares and allocated to a
share account, and she will be able to invest part or all of the
balance of her fees into the same share account.
2.
The Board has determined that Dr Glimcher will be an independent
Non-Executive Director, in accordance with the UK Corporate
Governance Code. In addition, the Company confirms that there are
no further disclosures to be made in connection with Dr Glimcher's
appointment in accordance with Listing Rule 9.6.13R.
3. "Scientific and Medical Expert" - The Board
designates Non Executive Directors whose expertise or backgrounds
as renowned medical scientists, researchers, or physicians mean
that they are able to bring scientific or industry expertise to the
Board's deliberations.
4.
With effect from 1 September 2017, the composition of the Board of
GSK will be as follows:
|
Sir
Philip
Hampton
|
Non-Executive
Chairman
|
|
Ms Emma
Walmsley
|
Chief
Executive Officer
|
|
Mr
Simon Dingemans
|
Chief
Financial Officer
|
|
Dr
Patrick Vallance
|
President,
R&D
|
|
Professor
Sir Roy Anderson
|
Independent
Non-Executive Director
|
|
Mr
Vindi Banga
|
Senior
Independent Non-Executive Director
|
|
Dr
Vivienne Cox
|
Independent
Non-Executive Director
|
|
Ms Lynn
Elsenhans
|
Independent
Non-Executive Director
|
|
Dr
Jesse Goodman
|
Independent
Non-Executive Director
|
|
Dr
Laurie Glimcher
|
Independent
Non-Executive Director
|
|
Ms Judy
Lewent
|
Independent
Non-Executive Director
|
|
Mr Urs
Rohner
|
Independent
Non-Executive Director
|
GSK - one of the world's
leading research-based pharmaceutical and healthcare companies - is
committed to improving the quality of human life by enabling people
to do more, feel better and live longer. For further information
please visit www.gsk.com.
|
GSK
enquiries:
|
|
|
|
|
|
Simon
Steel
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Eleanor
Bunch
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
|
|
|
|
US
Media enquiries:
|
Sarah
Alspach
|
+1 202
715 1048
|
(Washington,
DC)
|
|
|
Sarah
Spencer
|
+1 215
751 3335
|
(Philadelphia)
|
|
|
|
|
|
|
Analyst/Investor
enquiries:
|
Sarah
Elton-Farr
|
+44 (0)
20 8047 5194
|
(London)
|
|
|
Tom
Curry
|
+ 1 215
751 5419
|
(Philadelphia)
|
|
|
Gary
Davies
|
+44 (0)
20 8047 5503
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
Cautionary
statement regarding forward-looking statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
'Risk factors' in the company's Annual Report on Form 20-F for
2016.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: July
21, 2017
|
|
|
|
|
|
|
By: VICTORIA
WHYTE
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|